Ogsiveo, nirogacestat
Named-patient access overview. Ogsiveo is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Ogsiveo
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Ogsiveo
Ogsiveo (nirogacestat) is manufactured by SpringWorks Therapeutics and was approved by the US FDA in November 2023 for adult patients with progressing desmoid tumors who require systemic treatment. Desmoid tumors are a form of aggressive fibromatosis: locally invasive soft-tissue tumors that, while not metastatic, can cause significant morbidity through infiltration of surrounding structures. Ogsiveo is an oral, selective small-molecule gamma-secretase inhibitor; by reducing gamma-secretase activity it suppresses downstream Notch signalling and influences the Wnt / beta-catenin pathway activity implicated in desmoid biology, which is the mechanism supported by the DeFi Phase 3 pivotal trial.
Ogsiveo is taken by mouth twice daily as set out in the prescribing information, with monitoring for diarrhea, electrolyte disturbance, rash, headache, and hepatotoxicity. The label highlights ovarian toxicity, including premature ovarian insufficiency, as a notable risk in females of reproductive potential, and counselling on this risk is required before treatment. For international patients, Ogsiveo may be coordinated through Named Patient Program or personal-import pathways with the destination country's regulator and the patient's treating physician handling the documentation.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Ogsiveo
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Ogsiveo for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Ogsiveo is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list nirogacestat as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Expanded access records for nirogacestat that were marked “Available” on 17 October 2026:
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Access by country
Reserve Meds publishes a detailed country deep-dive for Ogsiveo in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Ogsiveo
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Ogsiveo if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Ogsiveo for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Ogsiveo through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Ogsiveo. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Ogsiveo through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Ogsiveo to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Ogsiveo to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Ogsiveo cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Ogsiveo?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.